The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Posts from this topic will be added to your daily email digest and your homepage feed. is an investigations editor and feature writer covering technology and the people who make, use, and are affected ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...

(RTTNews) - Lexicon Pharmaceuticals Inc. (LXRX) announced that the U.S. FDA raised no objections to advancing Pilavapadin into Phase 3 development following a successful End-of-Phase 2 meeting for the ...

A security vulnerability has been disclosed in the popular binary-parser npm library that, if successfully exploited, could result in the execution of arbitrary JavaScript. The vulnerability, tracked ...

Good afternoon, everyone. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Alex Morrison. I'm an associate on JPM's health care team. Today, it's my pleasure to introduce Lexicon ...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

There is a lot of enterprise data trapped in PDF documents. To be sure, gen AI tools have been able to ingest and analyze PDFs, but accuracy, time and cost have been less than ideal. New technology ...